- Home
- HEPS vs SLDB Comparison
HEPS vs SLDB Comparison
Compare HEPS & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HEPS | SLDB |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | Turkey | United States |
| Employees | N/A | 121 |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 935.9M | 932.9M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | HEPS | SLDB |
|---|---|---|
| Price | $2.54 | $8.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $3.07 | ★ $16.36 |
| AVG Volume (30 Days) | 516.7K | ★ 910.6K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,094,000.00 |
| Revenue This Year | $41.29 | N/A |
| Revenue Next Year | $27.99 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.15 | $3.79 |
| 52 Week High | $3.30 | $11.45 |
Technical Indicators
Market Signals| Indicator | HEPS | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 46.30 |
| Support Level | N/A | $8.16 |
| Resistance Level | N/A | $10.48 |
| Average True Range (ATR) | 0.00 | 0.40 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 0.00 | 32.33 |
Price Performance
Historical ComparisonAbout HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. It's portfolio offers its retail customers a wide selection of merchandise including electronics and non-electronics (including books, sports, toys, kids and baby products, cosmetics, furniture, etc). The Group derives revenue from the sales of goods, marketplace revenues and other revenues.
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.